Xenon Pharmaceuticals Inc (XENE) Ownership & Trading Activity
Institutional holders, insider transactions, and congressional trades for XENE. 13F holdings as of 2026-06-30.
In 13F filings for the quarter ended June 30, 2026, 303 institutions reported holding XENE, with 101.0 million shares worth $6.1 billion in aggregate.
Top Institutional Holders
| Institution | Shares | Value | Change |
|---|---|---|---|
| FMR | 9,647,998 | $582M | DECREASED |
| BlackRock | 7,522,482 | $454M | INCREASED |
| Avoro Capital Advisors | 5,777,777 | $349M | UNCHANGED |
| T. Rowe Price | 5,416,800 | $327M | INCREASED |
| Polar Capital Holdings | 4,570,556 | $276M | INCREASED |
Recent Insider Trades
| Insider | Type | Shares | Value | Date |
|---|---|---|---|---|
| Thomas Patrick Kelly (Chief Financial Officer) | EXERCISE | 7,500 | 2026-10-15 | |
| Thomas Patrick Kelly (Chief Financial Officer) | EXERCISE | 7,500 | 2026-10-15 | |
| Thomas Patrick Kelly (Chief Financial Officer) | BUY | 15,000 | $560K | 2026-09-30 |
| Ian Mortimer (PRESIDENT & CEO) | BUY | 30,000 | $1M | 2026-09-30 |
| Dawn Svoronos (Director) | EXERCISE | 5,144 | $42K | 2026-09-01 |
Full institutional holdings, insider history, and congressional trades for Xenon Pharmaceuticals Inc on SentiSense.